NTAGI committee recommends Covovax

New Delhi, April 29: The Standing Technical Sub-Committee of the NTAGI has recommended inclusion of the Serum Institute’s Covid jab Covovax in the national anti-coronavirus vaccination programme for children aged 12 to 17 years, sources said on Friday.
The National Technical Advisory Group on Immunisation (NTAGI) panel, at its meeting on Friday, also discussed reducing the gap between the second and precaution doses of vaccine from nine to six months and administering the additional dose early (before nine months) to those travelling abroad for education, employment, sporting events and business meetings.
But it could not reach a decision on the matter related to the precaution dose, sources said.
The vaccination of children aged five to 11 years was not on the agenda of the NTAGI Standing Technical Sub-Committee (STSC) meeting, they said.
On the Serum Institute’s vaccine Covovax, an official source said, “The COVID-19 working group of the NTAGI had earlier reviewed data related to Covovax and okayed it. The NTAGI’s Standing Technical Sub-Committee which met on Friday has recommended that the vaccine can be used in the covid vaccination drive for 12-17 years age group.” (PTI)